EC Paediatrics

Case Report Volume 12 Issue 3 - 2023

Thrombocytopenia and Giant Hemangioma: Know How to Evoke and Treat the Kasabach-Merritt Syndrome. A Case Report and Literature Review

Mohammed Mokhtar Bekkar1,2,3*, Amina Tari1,2 and Sakina Niar1,2

1Faculty of Medicine University Oran 1 “Ahmed Ben Bella”, Algeria
2Marfan Pediatric Department, Oran University Hospital Center, Algeria
3GRAS Research Laboratory, IEC Health Team, Algeria

*Corresponding Author: Mohammed Mokhtar Bekkar, Marfan Pediatric Department, Oran University Hospital Center and Faculty of Medicine University Oran 1 “Ahmed Ben Bella” and GRAS research laboratory, IEC Health Team, Algeria.
Received: February 16, 2023; Published: February 27, 2023

Introduction: Kasabach-Merritt syndrome is a rare form of vascular tumor that are often misdiagnosed, which is complicated by intra-tumor coagulopathy and requiring urgent management.

Objective: This review highlights the clinical presentation, histopathology, management, and treatment of Kasabach-Merritt syndrome. A clinical case compiled in the pediatric department of the university Hospital Center of Oran Algeria, is described to illustrate the presentation and our management of a patient with Kasabach-Merritt syndrome.

Observation: A female infant was admitted, on the thirtieth day of life, for a purplish red swelling of the left hemiface. He had hemolytic anemia, profound thrombocytopenia and consumptive coagulopathy. It was successfully managed with a combination of high dose of oral corticosteroids and vincristine.

Conclusion: Vincristine and oral corticosteroids were useful for our patient and may be considered an option for first-line therapy of Kasabach-Merritt syndrome. The absence of a codified therapeutic protocol makes the management of this tumor a real challenge.

Keywords: Kasabach-Merritt Syndrome; Thrombocytopenia; Hemangiomas; Coagulopathy; Vascular Tumor; Kaposiform Hemangioendothelioma

  1. Minard-Colin V., et al. “Les tumeurs mésenchymateuses du nouveau-né - Soft tissue tumors in neonates”. Archives de Pédiatrie7 (2009): 1039-1048.
  2. ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies .Available at "" (2022).
  3. Enjolras O., et al. “Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas”. The Journal of Pediatrics4 (1997): 631-640.
  4. Alvarez-Mendoza A., et al. “Histopathology of vascular lesions found in Kasabach-Merritt syndrome: review based on 13 cases”. Pediatric and Developmental Pathology6 (2000): 556-560.
  5. Drolet BA., et al. “Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma”. The Journal of Pediatrics1 (2013): 285-291.
  6. Kasabach HH and Merritt KK. “Capillary hemangioma with extensive purpura: report of a case”. American Journal of Diseases of Children 59 (1940): 1063-1070.
  7. Croteau SE., et al. “Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals”. The Journal of Pediatrics1 (2013): 142-147.
  8. Gözdaşoğlu S. “Kasabach-Merritt Syndrome in an Adult: A Comment”. Turkish Journal of Hematology1 (2019): 52-53.
  9. O’Rafferty C., et al. “Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon”. British Journal of Haematology 171 (2015): 38-51.
  10. Schmid I., et al. “Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options”. World Journal of Pediatrics4 (2018): 322-329.
  11. Zukerberg LR., et al. “Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis”. The American Journal of Surgical Pathology 17 (1993): 321-328.
  12. Rodriquez V., et al. “Kasabach-Merritt phenomenon: case series and retrospective review of the mayo clinic experience”. Journal of Pediatric Hematology/Oncology7 (2009): 522-526.
  13. Sarkar M., et al. “Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma”. Plastic and Reconstructive Surgery6 (1997): 1377-1386.
  14. Mahajan P., et al. “Kasabach-Merritt Phenomenon: Classic Presentation and Management Options”. Clinical Medicine Insights: Blood Disorders 10 (2017): 1179545X17699849.
  15. Ryan C., et al. “Kasabach-Merritt phenomenon: a single centre experience”. The European Journal of Haematology2 (2010): 97-104.
  16. Kelly M. “Kasabach-Merritt phenomenon”. Pediatric Clinics of North America5 (2010): 1085-1089.
  17. Hall GW. “Kasabach-Merritt syndrome: Pathogenesis and management”. British Journal of Haematology 112 (2001): 851-862.
  18. O’Rafferty C., et al. “Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon”. British Journal of Haematology 171 (2015): 38-51.


  1. Lyons LL., et al. “Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile Hemangioma”. The American Journal of Surgical Pathology5 (2004): 559-568.
  2. Le Huu AR., et al. “Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma”. The American Journal of Surgical Pathology 34 (2010): 1563-1573.
  3. Enjolras O., et al. “Uncommon benign infantile vascular tumors”. Advances in Dermatology 24 (2008): 105-124.
  4. Verheul HM., et al. “Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition”. Pediatric Research5 (1999): 562-565.
  5. Phillips WG and Marsden JR. “Kasabach-Merritt syndrome exacerbated by platelet transfusion”. Journal of the Royal Society of Medicine 86 (1993): 231-232.
  6. Pampin C., et al. “Intratumoral consumption of indium-111- labeled platelets in a child with splenic hemangioma and thrombocytopenia”. Journal of Pediatric Hematology/Oncology3 (2000): 256-258.
  7. Seon KS., et al. “Kasabach-Merritt syndrome: identification of platelet trapping in a tufted angioma by immunohistochemistry technique using monoclonal antibody to CD61”. Pediatric Dermatology5 (1999): 392-394.
  8. Ortel T., et al. “Antifibrinolytic therapy in the management of the kasabach merritt syndrome”. American Journal of Hematology1 (1988): 44-48.
  9. Larsen E., et al. “Kasabach-Merritt syndrome: therapeutic considerations”. Pediatrics 79 (1987): 971-980.
  10. Adams DM. “Special considerations in vascular anomalies: hematologic management”. Clinics in Plastic Surgery 38 (2011): 153-160.
  11. Zhou SY., et al. “Successful treatment of Kasabach-Merritt syndrome with transarterial embolization and corticosteroids”. Journal of Pediatric Surgery3 (2013): 673-676.
  12. Wananukul S., et al. “Treatment of Kasabaeh-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon”. International Journal of Dermatology 42 (2003) :741-748.
  13. Perez Payarols J., et al. “Treatment of life-threatening infantile hemangiomas with vincristine”. The New England Journal of Medicine 333 (1995): 69-70.
  14. Hu B., et al. “Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin”. Pediatric Hematology Oncology Journal6 (1998): 567-569.
  15. Chiu YE., et al. “Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon”. Pediatric Blood and Cancer 59 (2012): 934-938.
  16. Hermans DJJ., et al. “Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment”. Journal of Pediatric Hematology/Oncology 33 (2011): e171-e173.
  17. Shin HY., et al. “Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome”. Pediatrics International 42 (2000): 620-624.
  18. Deb G., et al. “Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon”. Medical and Pediatric Oncology 28 (1997): 358-361.
  19. Barlow C., et al. “Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy”. The Journal of Pediatrics3 (1998): 527-530.
  20. Haisley-Royster C., et al. “Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine”. Journal of Pediatric Hematology/Oncology6 (2002): 459-462.
  21. Ohtsuka T., et al. “Angioblastoma (Nakagawa) with hyperhidrosis, and relapse after a 10-year interval”. British Journal of Dermatology1 (2000): 223-224.
  22. Hauer JGU., et al. “Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach–Merritt phenomenon using four-drug regimen”. Pediatric Blood and Cancer 49 (2007): 852-872.
  23. Jiang BH and Liu LZ. “PI3K/PTEN signaling in tumorigenesis and angiogenesis”. Biochimica et Biophysica Acta 1784 (2008): 150-158.
  24. Perry B., et al. “AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo”. Archives of Dermatological Research 143 (2007): 504-506.
  25. Morris PN., et al. “Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations”. Journal of Molecular Medicine 83 (2005): 58-63.
  26. Ji Y., et al. “Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study”. International Journal of Cancer 141 (2017): 848-855.

Mohammed Mokhtar Bekkar., et al. Thrombocytopenia and Giant Hemangioma: Know How to Evoke and Treat the Kasabach-Merritt Syndrome. A Case Report and Literature Review. EC Paediatrics 12.3 (2023):66-75.